Skip to main content
NCBI home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1989;82(Suppl 17):23–29.

Efficacy of drug prophylaxis.

P A Phillips-Howard 1
PMCID: PMC1291934  PMID: 2693720

Abstract

With the spread of chloroquine resistant Plasmodium falciparum the control of malaria has become increasingly complex. In recent years, particular concern has arisen over how best to prevent malaria in non-immune international travellers. Prior to the recognition of the potential toxicity of some antimalarial drugs, malaria preventive guidelines switched from chloroquine to the newer compound antimalarial drugs and to amodiaquine; this adjustment was made when sentinel cases alerted clinicians that breakthrough infections occurred in travellers to East Africa taking chloroquine prophylaxis. Changes were also supported by data derived from field studies illustrating the effectiveness of these drugs for therapy in indigenous populations. However, international studies have now documented serious adverse reactions to pyrimethamine/dapsone, pyrimethamine/sulphadoxine, and amodiaquine, and caution is required with their use. Rates in British users concur with international estimates. Specialists preparing malaria preventive guidelines have, therefore, preferred to recommend the use of relatively safe antimalarial drugs, like chloroquine and proguanil, provided they offer non-immune travellers adequate protection against P. falciparum infections. Substantial difficulty has arisen, however, in the definition of 'adequate protection'. Field studies in indigenous communities with partial immunity can provide concise biological measures of parasite resistance to drugs. Unfortunately, these data cannot be used directly to determine the expected efficacy of chemoprophylactic drugs in non-immune populations. The transmission of malaria and the degree and intensity of resistance vary even within small geographical areas. Comprehensive patterns of resistance cannot be mapped out on a countrywide or regional basis for logistic reasons, and are restricted focally to discrete study locations.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
23

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brohult J., Rombo L., Sirleaf V., Bengtsson E. Weekly malaria prophylaxis: 300 or 600 mg chloroquine base. Lancet. 1979 Sep 8;2(8141):522–522. doi: 10.1016/s0140-6736(79)91571-x. [DOI] [PubMed] [Google Scholar]
  2. Bygbjerg I. C., Schapira A., Flachs H., Gomme G., Jepsen S. Mefloquine resistance of falciparum malaria from Tanzania enhanced by treatment. Lancet. 1983 Apr 2;1(8327):774–775. doi: 10.1016/s0140-6736(83)92070-6. [DOI] [PubMed] [Google Scholar]
  3. Campbell C. C., Chin W., Collins W. E., Teutsch S. M., Moss D. M. Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet. 1979 Dec 1;2(8153):1151–1154. doi: 10.1016/s0140-6736(79)92383-3. [DOI] [PubMed] [Google Scholar]
  4. Cook I. F., Cochrane J. P., Edstein M. D. Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis. Trans R Soc Trop Med Hyg. 1986;80(6):897–901. doi: 10.1016/0035-9203(86)90250-6. [DOI] [PubMed] [Google Scholar]
  5. Coosemans M. H., Barutwanayo M., Onori E., Otoul C., Gryseels B., Wéry M. Double-blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cycloguanil. Trans R Soc Trop Med Hyg. 1987;81(1):151–156. doi: 10.1016/0035-9203(87)90310-5. [DOI] [PubMed] [Google Scholar]
  6. Fogh S., Jepsen S., Effersøe P. Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg. 1979;73(2):228–229. doi: 10.1016/0035-9203(79)90220-7. [DOI] [PubMed] [Google Scholar]
  7. Fogh S., Schapira A., Bygbjerg I. C., Jepsen S., Mordhorst C. H., Kuijlen K., Ravn P., Rønn A., Gøtzsche P. C. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. Br Med J (Clin Res Ed) 1988 Mar 19;296(6625):820–822. doi: 10.1136/bmj.296.6625.820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Friman G., Nyström-Rosander C., Jonsell G., Björkman A., Lekås G., Svendsrup B. Agranulocytosis associated with malaria prophylaxis with Maloprim. Br Med J (Clin Res Ed) 1983 Apr 16;286(6373):1244–1245. doi: 10.1136/bmj.286.6373.1244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greenwood B. M., Greenwood A. M., Smith A. W., Menon A., Bradley A. K., Snow R. W., Sisay F., Bennett S., Watkins W. M., N'Jie A. B. A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children. Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):182–188. doi: 10.1016/0035-9203(89)90635-4. [DOI] [PubMed] [Google Scholar]
  10. Harries A. D., Forshaw C. J., Friend H. M. Malaria prophylaxis amongst British residents of Lilongwe and Kasungu districts, Malawi. Trans R Soc Trop Med Hyg. 1988;82(5):690–692. doi: 10.1016/0035-9203(88)90200-3. [DOI] [PubMed] [Google Scholar]
  11. Hatton C. S., Peto T. E., Bunch C., Pasvol G., Russell S. J., Singer C. R., Edwards G., Winstanley P. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986 Feb 22;1(8478):411–414. doi: 10.1016/s0140-6736(86)92371-8. [DOI] [PubMed] [Google Scholar]
  12. Henderson A., Rixom J. A. Personal antimosquito measures plus proguanil for malaria prophylaxis in southern Malaysia. Trans R Soc Trop Med Hyg. 1986;80(6):981–982. doi: 10.1016/0035-9203(86)90279-8. [DOI] [PubMed] [Google Scholar]
  13. Henderson A., Simon J. W., Melia W. Failure of malaria chemoprophylaxis with a proguanil-chloroquine combination in Papua New Guinea. Trans R Soc Trop Med Hyg. 1986;80(5):838–840. doi: 10.1016/0035-9203(86)90398-6. [DOI] [PubMed] [Google Scholar]
  14. Karwacki J. J., Webster H. K., Limsomwong N., Shanks G. D. Two cases of mefloquine resistant malaria in Thailand. Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):152–153. doi: 10.1016/0035-9203(89)90620-2. [DOI] [PubMed] [Google Scholar]
  15. Kean B. H. Chloroquine-resistant falciparum malaria from Africa. JAMA. 1979 Jan 26;241(4):395–395. [PubMed] [Google Scholar]
  16. Kollaritsch H., Stemberger H., Mailer H., Kremsner P., Kollaritsch R., Leimer R., Wiedermann G. Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria. Trans R Soc Trop Med Hyg. 1988;82(4):524–529. doi: 10.1016/0035-9203(88)90492-0. [DOI] [PubMed] [Google Scholar]
  17. Lagrave M., Stahel E., Betschart B. The influence of various types of breakfast on chloroquine levels. Trans R Soc Trop Med Hyg. 1985;79(4):559–559. doi: 10.1016/0035-9203(85)90095-1. [DOI] [PubMed] [Google Scholar]
  18. Limsomwong N., Pang L. W., Singharaj P. Malaria prophylaxis with proguanil in children living in a malaria-endemic area. Am J Trop Med Hyg. 1988 Mar;38(2):231–236. doi: 10.4269/ajtmh.1988.38.231. [DOI] [PubMed] [Google Scholar]
  19. Lobel H. O., Roberts J. M., Somaini B., Steffen R. Efficacy of malaria prophylaxis in American and Swiss travelers to Kenya. J Infect Dis. 1987 Jun;155(6):1205–1209. doi: 10.1093/infdis/155.6.1205. [DOI] [PubMed] [Google Scholar]
  20. McLarty D. G., Webber R. H., Jaatinen M., Kihamia C. H., Murru M., Kumano M., Aubert B., Magnuson L. W. Chemoprophylaxis of malaria in non-immune residents in Dar es Salaam, Tanzania. Lancet. 1984 Sep 22;2(8404):656–659. doi: 10.1016/s0140-6736(84)91223-6. [DOI] [PubMed] [Google Scholar]
  21. Merkli B., Richle R. W. Studies on the resistance to single and combined antimalarials in the Plasmodium berghei mouse model. Acta Trop. 1980 Sep;37(3):228–231. [PubMed] [Google Scholar]
  22. Miller K. D., Lobel H. O., Satriale R. F., Kuritsky J. N., Stern R., Campbell C. C. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986 May;35(3):451–458. doi: 10.4269/ajtmh.1986.35.451. [DOI] [PubMed] [Google Scholar]
  23. Moran J. S., Bernard K. W., Greenberg A. E., Patchen L., Waterman S., Bennet H. S. Failure of chloroquine treatment to prevent malaria in Americans in West Africa. JAMA. 1987 Nov 6;258(17):2376–2377. [PubMed] [Google Scholar]
  24. Najera J. A. Malaria and the work of WHO. Bull World Health Organ. 1989;67(3):229–243. [PMC free article] [PubMed] [Google Scholar]
  25. Nevill C. G., Watkins W. M., Carter J. Y., Munafu C. G. Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. BMJ. 1988 Aug 6;297(6645):401–403. doi: 10.1136/bmj.297.6645.401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pang L. W., Limsomwong N., Singharaj P., Canfield C. J. Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area. Bull World Health Organ. 1989;67(1):51–58. [PMC free article] [PubMed] [Google Scholar]
  27. Pang L., Limsomwong N., Singharaj P. Prophylactic treatment of vivax and falciparum malaria with low-dose doxycycline. J Infect Dis. 1988 Nov;158(5):1124–1127. doi: 10.1093/infdis/158.5.1124. [DOI] [PubMed] [Google Scholar]
  28. Pearlman E. J., Lampe R. M., Thiemanun W., Kennedy R. S. Chemosuppressive field trials in Thailand. III. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by a sulfadoxine-pyrimethamine combination. Am J Trop Med Hyg. 1977 Nov;26(6 Pt 1):1108–1115. [PubMed] [Google Scholar]
  29. Pearlman E. J., Thiemanun W., Castaneda B. F. Chemosuppressive field trials in Thailand. II. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by a diformyldapsone-pyrimethamine combination. Am J Trop Med Hyg. 1975 Nov;24(6 Pt 1):901–909. [PubMed] [Google Scholar]
  30. Peto T. E., Gilks C. F. Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet. 1986 May 31;1(8492):1256–1261. doi: 10.1016/s0140-6736(86)91395-4. [DOI] [PubMed] [Google Scholar]
  31. Saarinen M., Thoren E., Iyambo N., Carlstedt A., Shinyafa L., Fernanda M., Paajanen H., Paajanen K., Indongo I., Rombo L. Mass proguanil prophylaxis. Lancet. 1987 Apr 25;1(8539):985–986. doi: 10.1016/s0140-6736(87)90341-2. [DOI] [PubMed] [Google Scholar]
  32. Spencer H. C., Oloo A. J., Watkins W. W., Sixsmith D. G., Churchill F. C., Koech D. K. Amodiaquine more effective than chloroquine against Plasmodium falciparum malaria on Kenya coast. Lancet. 1984 Apr 28;1(8383):956–957. doi: 10.1016/s0140-6736(84)92406-1. [DOI] [PubMed] [Google Scholar]
  33. Stahel E., Druilhe P., Gentilini M. Antagonism of chloroquine with other antimalarials. Trans R Soc Trop Med Hyg. 1988;82(2):221–221. doi: 10.1016/0035-9203(88)90417-8. [DOI] [PubMed] [Google Scholar]
  34. Watkins W. M., Brandling-Bennett A. D., Oloo A. J., Howells R. E., Gilles H. M., Koech D. K. Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. Lancet. 1987 Jan 17;1(8525):125–128. doi: 10.1016/s0140-6736(87)91966-0. [DOI] [PubMed] [Google Scholar]
  35. Watkins W. M., Sixsmith D. G., Spencer H. C., Boriga D. A., Kariuki D. M., Kipingor T., Koech D. K. Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet. 1984 Feb 18;1(8373):357–359. doi: 10.1016/s0140-6736(84)90410-0. [DOI] [PubMed] [Google Scholar]
  36. Win K., Thwe Y., Lwin T. T., Win K. Combination of mefloquine with sulfadoxine-pyrimethamine compared with two sulfadoxine-pyrimethamine combinations in malaria chemoprophylaxis. Lancet. 1985 Sep 28;2(8457):694–695. doi: 10.1016/s0140-6736(85)92933-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES